Skip to content

VANSCHOONBEEK FARMA: sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

VANSCHOONBEEK FARMA

BE 0678.754.530
NACE 47.730, Retail sale of pharmaceutical products
NACE division 47, Retail trade all sizesfiscal years 2021 to 202516,997 to 32,568 sector peers per ratio

Summary

fiscal year 2025

VANSCHOONBEEK FARMA does better than half of its sector on 3 of the 8 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • Return on equitybetter than 93%
  • Return on assetsbetter than 81%
  • Interest coveragebetter than 71%
Points to watch
  • Current ratiobetter than 10%
  • Long-term debt ratiobetter than 14%
  • Debt to equitybetter than 14%

Solvency and debt

How soundly the company is financed.
Solvency
16.7%▼2025

Solvency is below 70% of 32,488 sector peers: less favourable than the median.

Position against the sector improving since 2021.

20212022202320242025
Debt to equity
4.99▲2025

Debt to equity is above 86% of 32,106 sector peers: in the least favourable quarter.

Position against the sector improving since 2021.

20212022202320242025
Long-term debt ratio
2.49▼2025

The long-term debt ratio is above 86% of 16,997 sector peers: in the least favourable quarter.

Position against the sector improving since 2021.

20212022202320242025
Interest coverage
19.74▲2025

Interest coverage is above 71% of 29,199 sector peers: more favourable than the median.

Position against the sector stable since 2021.

20212022202320242025

Liquidity

Whether it can pay its short-term bills.
Current ratio
0.47▼2025

The current ratio is below 90% of 32,316 sector peers: in the least favourable quarter.

Position against the sector improving since 2021.

20212022202320242025
Working-capital ratio
-22.1%▼2025

The working-capital ratio is below 85% of 32,412 sector peers: in the least favourable quarter.

Position against the sector improving since 2021.

20212022202320242025

Profitability

What the company earns on its assets and its sales.
Return on equity
88.8%▲2025

Return on equity is above 93% of 27,017 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Return on assets
14.8%▲2025

Return on assets is above 81% of 32,568 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025

Not computable

Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 29 September 2026 via checked.be.